Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines

International Journal of Oncology

Volumn 41, Issue 2, 2012, Pages 733-744

  Kneissl, Julia ^a   Keller, Simone ^a   Lorber, Thomas ^a   Heindl, Stefan ^a   Keller, Gisela ^a   Drexler, Ingo ^a,c   Hapfelmeier, Alexander ^a   Höfler, Heinz ^a,b   Luber, Birgit ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Amphiregulin; Cetuximab; Epidermal growth factor receptor; Gastric cancer

Indexed keywords

AMPHIREGULIN; B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; SCATTER FACTOR RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG RESPONSE; GENE MUTATION; HUMAN; HUMAN CELL; LIGAND BINDING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; STOMACH CANCER;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MUTATION; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863576730     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1479     Document Type: Article

References (49)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Wang SJ, Emery R, Fuller CD, Kim JS, Sittig DF and Thomas CR: Conditional survival in gastric cancer: a SEER database analysis. Gastric Cancer 10: 153-158, 2007. (Pubitemid 47547297)
3. Verdecchia A, Santaquilani M and Sant M: Survival for cancer patients in Europe. Ann Ist Super Sanita 45: 315-324, 2009.
4. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK and Kim WH: EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 52: 738-746, 2008. (Pubitemid 351600058)
5. Liang Z, Zeng X, Gao J, et al: Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer 8: 363, 2008.
6. Pinto C, Di Fabio F, Barone C, et al: Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer 101: 1261-1268, 2009.
7. Lordick F, Luber B, Lorenzen S, et al: Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 102: 500-505, 2010.
8. Kim C, Lee JL, Ryu MH, et al: A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs 29: 366-373, 2011.
9. Luber B, Deplazes J, Keller G, et al: Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer 11: 509, 2011.
10. Lievre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995, 2006.
11. Goldstein NI, Prewett M, Zuklys K, Rockwell P and Mendelsohn J: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1: 1311-1318, 1995.
12. Harris RC, Chung E and Coffey RJ: EGF receptor ligands. Exp Cell Res 284: 2-13, 2003. (Pubitemid 36331964)
13. Higashiyama S, Abraham JA, Miller J, Fiddes JC and Klagsbrun M: A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 251: 936-939, 1991. (Pubitemid 21926188)
14. Komurasaki T, Toyoda H, Uchida D and Morimoto S: Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4. Oncogene 15: 2841-2848, 1997. (Pubitemid 28004573)
15. Shoyab M, Plowman GD, McDonald VL, Bradley JG and Todaro GJ: Structure and function of human amphiregulin: a member of the epidermal growth factor family. Science 243: 1074-1076, 1989. (Pubitemid 19072586)
16. Strachan L, Murison JG, Prestidge RL, Sleeman MA, Watson JD and Kumble KD: Cloning and biological activity of epigen, a novel member of the epidermal growth factor superfamily. J Biol Chem 276: 18265-18271, 2001.
17. Watanabe T, Shintani A, Nakata M, et al: Recombinant human betacellulin. Molecular structure, biological activities, and receptor interaction. J Biol Chem 269: 9966-9973, 1994.
18. Prewett M, Rockwell P, Rockwell RF, et al: The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 19: 419-427, 1996.
19. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25: 3230-3237, 2007. (Pubitemid 47325606)
20. Jacobs B, De Roock W, Piessevaux H, et al: Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 27: 5068-5074, 2009.
21. Bardelli A and Siena S: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28: 1254-1261, 2010.
22. Krumbach R, Schuler J, Hofmann M, Giesemann T, Fiebig HH and Beckers T: Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer 47: 1231-1243, 2011.
23. Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG and Weiser MR: HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res 17: 472-482, 2011.
24. Heindl S, Eggenstein E, Keller S, et al: Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines. J Cancer Res Clin Oncol: Jan 31, 2012 (Epub ahead of print).
25. Kim IJ, Park JH, Kang HC, et al: Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Hum Genet 114: 118-120, 2003. (Pubitemid 38165543)
26. Han SW, Oh DY, Im SA, et al: Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 100: 298-304, 2009.
27. Paull KD, Shoemaker RH, Hodes L, et al: Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81: 1088-1092, 1989. (Pubitemid 19175145)
28. Boyd MR and Paull KD: Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 34: 91-109, 1995.
29. Luo FR, Yang Z, Dong H, et al: Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Cancer Chemother Pharmacol 56: 455-464, 2005. (Pubitemid 41549146)
30. Robert F, Ezekiel MP, Spencer SA, et al: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19: 3234-3243, 2001. (Pubitemid 32591441)
31. Baselga J, Pfister D, Cooper MR, et al: Phase I studies of antiepidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18: 904-914, 2000. (Pubitemid 30106623)
32. Loughrey MB, Waring PM, Tan A, et al: Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer 6: 301-310, 2007. (Pubitemid 47175009)
33. Pan Q, Pao W and Ladanyi M: Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 7: 396-403, 2005. (Pubitemid 41149655)
34. Marchetti A, Martella C, Felicioni L, et al: EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23: 857-865, 2005. (Pubitemid 46224186)
35. Bremm A, Walch A, Fuchs M, et al: Enhanced activation of epidermal growth factor receptor caused by tumor-derived E-cadherin mutations. Cancer Res 68: 707-714, 2008. (Pubitemid 351206746)
36. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043, 2007. (Pubitemid 46799492)
37. Agarwal S, Zerillo C, Kolmakova J, et al: Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br J Cancer 100: 941-949, 2009.
38. Guo A, Villen J, Kornhauser J, et al: Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 105: 692-697, 2008. (Pubitemid 351171770)
39. Asaoka Y, Tada M, Ikenoue T, et al: Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. Biochem Biophys Res Commun 394: 1042-1046, 2010.
40. Tinhofer I, Klinghammer K, Weichert W, et al: Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res 17: 5197-5204, 2011.
41. Yonesaka K, Zejnullahu K, Lindeman N, et al: Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res 14: 6963-6973, 2008.
42. Yasumoto K, Yamada T, Kawashima A, et al: The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer. Clin Cancer Res 17: 3619-3630, 2011.
43. Kitadai Y, Yasui W, Yokozaki H, et al: Expression of amphiregulin, a novel gene of the epidermal growth factor family, in human gastric carcinomas. Jpn J Cancer Res 84: 879-884, 1993. (Pubitemid 23262449)
44. Dong J, Opresko LK, Chrisler W, et al: The membrane-anchoring domain of epidermal growth factor receptor ligands dictates their ability to operate in juxtacrine mode. Mol Biol Cell 16: 2984-2998, 2005. (Pubitemid 40741241)
45. Inno A, Salvatore MD, Cenci T, et al: Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer 10: 325-332, 2011.
46. Stommel JM, Kimmelman AC, Ying H, et al: Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318: 287-290, 2007. (Pubitemid 47574858)
47. Kim IJ, Park JH, Kang HC, et al: Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Hum Genet 114: 118-120, 2003. (Pubitemid 38165543)
48. Mita H, Toyota M, Aoki F, et al: A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth. BMC Cancer 9: 198, 2009.
49. Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H and Tahara E: Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 189: 227-232, 1992. (Pubitemid 23030031)